Global Mycoplasma Testing Market is Anticipated to Witness High Growth Owing to Increasing Outsourcing of Testing Services

Global Mycoplasma Testing Market is Anticipated to Witness High Growth Owing to Increasing Outsourcing of Testing Services

 Mycoplasma testing helps detect and eliminate mycoplasma contamination from cell cultures and products intended for research, therapeutic applications, or commercial manufacturing. The global mycoplasma testing market is primarily driven by growing R&D spending on biopharmaceuticals and rising stringent regulations regarding mycoplasma contamination.

The Global Mycoplasma Testing Market is estimated to be valued at US$ 997.8 MN in 2024 and is expected to exhibit a CAGR of 9.7% over the forecast period 2024 to 2031.


Key Takeaways
Key players operating in the Global Mycoplasma Testing Market Size are Charles River Laboratories International, Merck KGaA, Lonza Group Ltd, Roche Diagnostics, Thermo Fisher Scientific, Merck, InvivoGen, Creative Bioarray.

The key opportunities in the mycoplasma testing market include growing cell therapy industry and increasing adoption of mycoplasma testing in vaccine manufacturing. The global cell therapy market size was valued at US$ 9.5 billion in 2021 and is expected to grow at a CAGR of 14.5% from 2022-2030. Mycoplasma testing plays a crucial role in ensuring cell identity, potency and viability in cell therapy products.

The key players in the mycoplasma testing market are focusing on expanding their geographical presence. For instance, in 2021, Merck partnered with several private and institutional customers in Asia Pacific to support their mycoplasma testing needs. Similarly, Lonza launched a mycoplasma testing service in China in 2022 to meet increasing outsourcing demands from local pharmaceutical and biotech companies.

Market Drivers
rising stringent regulations regarding mycoplasma contamination: Stringent regulations laid down by regulatory bodies such as FDA and EMA have mandated mycoplasma testing at multiple stages of biopharmaceutical manufacturing, which is a key driver for the market.

Market Restraints
high cost of instruments: Sophisticated instruments required for mycoplasma testing such as PCR, ELFA and bioassay make the overall testing cost prohibitive, especially for small and medium biopharma companies, which acts as a restraint.
Segment Analysis

The global mycoplasma testing market is dominated by the kits & reagents segment which accounted for nearly 60% share of the overall market in 2024. This segment witnessed high demand as mycoplasma testing is predominantly performed using kits & reagents. Testing service providers offer a variety of kits and reagents to cater to the varied needs of end users from research to clinical testing. The availability of customized kits and reagents tailored to specific needs further boosted the segment's growth. The instruments segment captured around 20% share owing to increasing uptake of automated instruments to ensure quick, reliable, and high-throughput screening of mycoplasma contamination. Advancements in instrument technology resulted in the launch of compact systems with automation and intelligence for on-demand testing requirements.

Global Analysis

On a regional level, North America dominated the mycoplasma testing market in 2024 with over 45% revenue share. This can be primarily attributed to well-established pharmaceutical and biotechnology industries in the US and Canada that invest heavily in R&D activities. Stringent regulations governing cell line authentication and product quality assurance across industries also augmented market growth. Europe captured nearly 30% share in 2024 owing to the large presence of medical device companies, contract research organizations, and growing biopharmaceutical sector. Asia Pacific exhibited the fastest growth rate during the forecast period owing to rising biologics production, increasing governmental focus on healthcare infrastructure, and progressive expansion of pharmaceutical industries in countries like China, India, and South Korea.
 
 
Get more insights on This Topic- Global Mycoplasma Testing Market

Explore More Articles - Washed Silica Sand Market